By the Numbers

By the Numbers

December 30, 2016
2 min read

ILC coverage, HCV guidelines, FDA approvals among 2016 hot topics in hepatology

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

New data presented at the 2016 International Liver Congress, new guidelines on the management of hepatitis C virus infection from EASL and the WHO, and several new FDA approvals were among the most popular news topics covered by this year.

To recap the year’s hottest topics in the specialty, we have compiled a list of the top 10 most read news articles in hepatology presented by in 2016.

1. First patient treated in phase 3 trial for HCC medication Pexa-Vec

Researchers at the University of Tennessee Medical Center treated the first patient in the phase 3 clinical trial for the hepatocellular carcinoma medication Pexa-Vec, according to an announcement we reported in August. Read more

2. EASL releases 2016 HCV recommendations

During a special conference in September, EASL released its 2016 recommendations for the treatment of hepatitis C. The findings were simultaneously published in the Journal of Hepatology. Read more

3. UDCA fails to improve mortality in primary biliary cirrhosis

The use of ursodeoxycholic acid for primary biliary cholangitis failed to reduce all-cause mortality, according to results of a systematic review presented at the International Liver Congress 2016. Read more

4. WHO issues updated HCV guidelines for treatment

Due to the rapid development and evolution of direct-acting viral treatments, WHO issued updated guidelines for the screening, care and treatment of individuals with chronic hepatitis C virus infection at the International Liver Congress. Read more

5. VIDEO: SVR does not equate to a cure in HCV

In an exclusive video from the International Liver Congress 2016, Ronald Koretz, MD, Emeritus professor of medicine at University of California Los Angeles School of Medicine, discussed results of a systematic review that asks: Does sustained virologic response represent a cure for hepatitis C virus infection? Watch now

6. FDA approves Zepatier for HCV genotypes 1, 4

In January, Merck announced the FDA approved Zepatier for the treatment of adult patients with chronic hepatitis C virus genotype 1 and 4 infection, with or without ribavirin. Read more

7. 24-norursodeoxycholic acid improves ALP in primary sclerosing cholangitis

In a phase 2 dose finding study presented in the Late Breakers session at International Liver Congress, patients with primary sclerosing cholangitis treated with 24-norursodeoxycholic acid saw improved alkaline phosphatase serum and other cholestasis. Read more

8. FDA approves Epclusa for all HCV genotypes

In June, the FDA announced it approved Epclusa for the treatment of all chronic hepatitis C virus genotypes in adults with and without cirrhosis. For patients with moderate to severe cirrhosis, it was approved in combination with ribavirin. Read more

9. Merck wins $2.54 billion in HCV drug patent infringement suit against Gilead

A jury in the U.S. District Court for the District of Delaware ordered Gilead Sciences to pay $2.54 billion in damages for infringing upon Merck subsidiary Idenix Pharmaceuticals’ patent for methods used to develop drugs based on sofosbuvir, including Sovaldi and Harvoni, which are used to treat patients with hepatitis C virus infection. Just recently reported earlier this month, this is already one of our most read hepatology articles of the year. Read more

10. Elafibranor safely reduces NASH without worsening fibrosis

In a phase 2 study, elafibranor was well-tolerated and led to resolved nonalcoholic steatohepatitis without worsening fibrosis, according to published findings we reported in February. Read more

Honorable mention: The FDA approved Ocaliva for primary biliary cholangitis in May of this year. Read more